Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.

Publication ,  Journal Article
Marquis-Gravel, G; Roe, MT; Robertson, HR; Harrington, RA; Pencina, MJ; Berdan, LG; Hammill, BG; Faulkner, M; Muñoz, D; Fonarow, GC; Fintel, DJ ...
Published in: JAMA Cardiol
May 1, 2020

IMPORTANCE: Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question. OBJECTIVE: To report the rationale and design for a randomized clinical trial to determine the optimal dosage of aspirin to be used for secondary prevention of ASCVD, using an innovative research method. DESIGN, SETTING, AND PARTICIPANTS: This pragmatic, open-label, patient-centered, randomized clinical trial is being conducted in 15 000 patients within the National Patient-Centered Clinical Research Network (PCORnet), a distributed research network of partners including clinical research networks, health plan research networks, and patient-powered research networks across the United States. Patients with established ASCVD treated in routine clinical practice within the network are eligible. Patient recruitment began in April 2016. Enrollment was completed in June 2019. Final follow-up is expected to be completed by June 2020. INTERVENTIONS: Participants are randomized on a web platform in a 1:1 fashion to either 81 mg or 325 mg of aspirin daily. MAIN OUTCOMES AND MEASURES: The primary efficacy end point is the composite of all-cause mortality, hospitalization for nonfatal myocardial infarction, or hospitalization for a nonfatal stroke. The primary safety end point is hospitalization for major bleeding associated with a blood-product transfusion. End points are captured through regular queries of the health systems' common data model within the structure of PCORnet's distributed data environment. CONCLUSIONS AND RELEVANCE: As a pragmatic study and the first interventional trial conducted within the PCORnet electronic data infrastructure, this trial is testing several unique and innovative operational approaches that have the potential to disrupt and transform the conduct of future patient-centered randomized clinical trials by evaluating treatments integrated in clinical practice while at the same time determining the optimal dosage of aspirin for secondary prevention of ASCVD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02697916.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

May 1, 2020

Volume

5

Issue

5

Start / End Page

598 / 607

Location

United States

Related Subject Headings

  • Stroke
  • Secondary Prevention
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Female
  • Aspirin
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Marquis-Gravel, G., Roe, M. T., Robertson, H. R., Harrington, R. A., Pencina, M. J., Berdan, L. G., … Jones, W. S. (2020). Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiol, 5(5), 598–607. https://doi.org/10.1001/jamacardio.2020.0116
Marquis-Gravel, Guillaume, Matthew T. Roe, Holly R. Robertson, Robert A. Harrington, Michael J. Pencina, Lisa G. Berdan, Bradley G. Hammill, et al. “Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.JAMA Cardiol 5, no. 5 (May 1, 2020): 598–607. https://doi.org/10.1001/jamacardio.2020.0116.
Marquis-Gravel G, Roe MT, Robertson HR, Harrington RA, Pencina MJ, Berdan LG, et al. Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiol. 2020 May 1;5(5):598–607.
Marquis-Gravel, Guillaume, et al. “Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.JAMA Cardiol, vol. 5, no. 5, May 2020, pp. 598–607. Pubmed, doi:10.1001/jamacardio.2020.0116.
Marquis-Gravel G, Roe MT, Robertson HR, Harrington RA, Pencina MJ, Berdan LG, Hammill BG, Faulkner M, Muñoz D, Fonarow GC, Nallamothu BK, Fintel DJ, Ford DE, Zhou L, Daugherty SE, Nauman E, Kraschnewski J, Ahmad FS, Benziger CP, Haynes K, Merritt JG, Metkus T, Kripalani S, Gupta K, Shah RC, McClay JC, Re RN, Geary C, Lampert BC, Bradley SM, Jain SK, Seifein H, Whittle J, Roger VL, Effron MB, Alvarado G, Goldberg YH, VanWormer JL, Girotra S, Farrehi P, McTigue KM, Rothman R, Hernandez AF, Jones WS. Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiol. 2020 May 1;5(5):598–607.

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

May 1, 2020

Volume

5

Issue

5

Start / End Page

598 / 607

Location

United States

Related Subject Headings

  • Stroke
  • Secondary Prevention
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Female
  • Aspirin
  • 3201 Cardiovascular medicine and haematology